Checkout my substack for in-depth thesis on companies https://t.co/VU9Alk6wjU

9/ Disclaimer: This stock analysis is for informational purposes only and does not constitute financial advice. Always do your own research and consult with a qualified financial advisor before making any investment decisions.

8/ Join the movement: 750,000+ CFD, Forex, and commodities traders have made https://t.co/UZmy9JfGgV their choice👇👇Link below https://t.co/vJrDnekcDn

7/ Final Take Short-Term: Tactical Buy Long-Term: Strategic Hold $PRAX is no longer speculative If ulixacaltamide lands FDA approval + commercial traction, this could be a generational re-rating If not, it’s a high-beta unwind

6/ $PRAX Forecasts & Risk Short-term glide path: $172–$185 Long-term projection: $400+ by 2027 Tail risk: $128–$140 Sentiment: Euphoric Regulatory risk: Real This is a clinical-stage setup with asymmetric upside

5/ $PRAX Tactical Entry Zones Aggressive: Hold above $168.50 with volume > 5M Moderate: Retest $160–$162 zone Conservative: Wait for FDA submission (early 2026) Stop-loss: $150 Target: $185–$195

4/ $PRAX Sentiment Snapshot Two Phase 3 trials hit primary + secondary endpoints Benefits visible by Week 2, sustained through Week 8 Guggenheim raised target to $350 Truist lifted target to $360 Translation: Street is catching up — tape is leading

3/ $PRAX Price Action Volume: 6.4M+ shares traded RSI: breakout zone MACD: bullish crossover Float: tight This is a revaluation — not a speculative pop

2/ What Is $PRAX? Clinical-stage biotech targeting CNS disorders Lead candidate: Ulixacaltamide Treats essential tremor (ET) Rapid onset, sustained efficacy, minimal sedation Addresses a condition affecting 10M+ globally This isn’t just a drug — it’s a category shift

1/ $PRAX closed at $162.71 on Oct 16 Then climbed +3.93% pre-market to $169.10 That’s a +200%+ move in under 24 hours This isn’t just momentum — it’s clinical ignition Let’s decode the setup

Praxis Precision Medicines / $PRAX : From Speculative to Blockbuster — Is This the Biotech Repricing? https://t.co/FUTP96h6nP #PRAX #BusinessNews #StocksToWatch

9/ Disclaimer: This stock analysis is for informational purposes only and does not constitute financial advice. Always do your own research and consult with a qualified financial advisor before making any investment decisions.

8/ Join the movement: 750,000+ CFD, Forex, and commodities traders have made https://t.co/UZmy9JfGgV their choice👇👇Link below https://t.co/vJrDnekcDn

7/ Final Take Short-Term: Tactical Buy Long-Term: Strategic Hold $ABVE is no longer just a plant-based ingredient company If distribution scales + tokenized traceability lands, this could be a generational re-rating If not, it’s a high-beta unwind

6/ $ABVE Forecasts & Risk Short-term glide path: $5.80–$6.40 Long-term projection: $9–$12 by 2027 Tail risk: $4.20–$4.60 Sentiment: Bullish Execution risk: Moderate This is a food-tech setup with asymmetric upside

5/ $ABVE Tactical Entry Zones Aggressive: Hold above $5.50 with volume > 6M Moderate: Retest $5.10–$5.30 zone Conservative: Wait for Palm Global integration update Stop-loss: $4.80 Target: $6.40–$6.80

4/ $ABVE Sentiment Snapshot Acquired Palm Global for global distribution Appointed auditor with crypto + tokenized asset expertise Climate + supply chain volatility boosting demand Translation: Tape is leading — Street is catching up

3/ $ABVE Price Action Volume: 7.4M+ shares traded RSI: breakout zone MACD: bullish crossover Float: tight This is a platform pivot — not a speculative pop

2/ What Is $ABVE? Vertically integrated food-tech company Focus: Proprietary seed genetics Ingredient manufacturing Branded consumer products Blockchain-based traceability This isn’t just food — it’s infrastructure

1/ $ABVE closed at $5.06 on Oct 15 Then surged +9.45% pre-market to $5.54 That’s a +28% move in under 24 hours This isn’t just momentum — it’s a strategic re-pricing Let’s decode the setup

Above Food Ingredients / $ABVE: From Plant-Based to Platform Play — Is This the Next Food-Tech Inflection? https://t.co/cfabn0dW68 #ABVE #business #stocks #Finance